Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Digitoxin
- Accession Number
- DB01396
- Type
- Small Molecule
- Groups
- Approved
- Description
A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665)
- Structure
Structure for DB01396 (Digitoxin)
- Synonyms
- Crystodigin (tn)
- Digitoksin
- Digitoxin
- Digitoxinum
- Digitoxoside
- External IDs
- NSC-7529
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Digitaline Welcker Tab 0.1mg Tablet .1 mg Oral Welcker Lyster Ltd., Division Of Technilab Inc. 1951-12-31 2001-09-05 Canada 
- International/Other Brands
- Crystodigin / Tardigal
- Categories
- Anti-Arrhythmia Agents
- Carbohydrates
- Cardanolides
- Cardenolides
- Cardiac Glycosides
- Cardiac Therapy
- Cardiotonic Agents
- Cardiovascular Agents
- Cardiovascular System
- Cytochrome P-450 CYP3A4 Substrates
- Digitalis Glycosides
- Enzyme Inhibitors
- Glycosides
- P-glycoprotein/ABCB1 Substrates
- Protective Agents
- Steroids
- UNII
- E90NZP2L9U
- CAS number
- 71-63-6
- Weight
- Average: 764.9391
Monoisotopic: 764.434692134 - Chemical Formula
- C41H64O13
- InChI Key
- WDJUZGPOPHTGOT-XUDUSOBPSA-N
- InChI
- InChI=1S/C41H64O13/c1-20-36(46)29(42)16-34(49-20)53-38-22(3)51-35(18-31(38)44)54-37-21(2)50-33(17-30(37)43)52-25-8-11-39(4)24(15-25)6-7-28-27(39)9-12-40(5)26(10-13-41(28,40)47)23-14-32(45)48-19-23/h14,20-22,24-31,33-38,42-44,46-47H,6-13,15-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27+,28-,29+,30+,31+,33+,34+,35+,36-,37-,38-,39+,40-,41+/m1/s1
- IUPAC Name
- 4-[(1S,2S,5S,7R,10R,11S,14R,15R)-5-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-11-hydroxy-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-14-yl]-2,5-dihydrofuran-2-one
- SMILES
- [H][[email protected]]12CC[[email protected]]3([H])[[email protected]]([H])(CC[[email protected]]4(C)[[email protected]](CC[[email protected]]34O)C3=CC(=O)OC3)[[email protected]@]1(C)CC[[email protected]@H](C2)O[[email protected]]1C[[email protected]](O)[[email protected]](O[[email protected]]2C[[email protected]](O)[[email protected]](O[[email protected]]3C[[email protected]](O)[[email protected]](O)[[email protected]@H](C)O3)[[email protected]@H](C)O2)[[email protected]@H](C)O1
Pharmacology
- Indication
For the treatment and management of congestive cardiac insufficiency, arrhythmias and heart failure.
- Structured Indications
- Not Available
- Pharmacodynamics
Digitoxin is a cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting (From Martindale, The Extra Pharmacopoeia, 30th ed, p665). Unlike digoxin (which is eliminated from the body via the kidneys), it is eliminated via the liver, so could be used in patients with poor or erratic kidney function. However, it is now rarely used in current UK medical practice. While there have been several controlled trials which have shown digoxin to be effective in a proportion of patients treated for heart failure, there is not the same strong evidence base for digitoxin, although it is presumed to be similarly effective.
- Mechanism of action
Digitoxin inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Digitoxin also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential.
Target Actions Organism ASodium/potassium-transporting ATPase subunit alpha-1 inhibitorHuman - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
Hepatic.
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
Digitoxin exhibits similar toxic effects to the more-commonly used digoxin, namely: anorexia, nausea, vomiting, diarrhoea, confusion, visual disturbances, and cardiac arrhythmias.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 10-hydroxycamptothecin Digitoxin may decrease the cardiotoxic activities of 10-hydroxycamptothecin. Investigational 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide Digitoxin may decrease the cardiotoxic activities of 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide. Experimental 2-chloroethyl-3-sarcosinamide-1-nitrosourea Digitoxin may decrease the cardiotoxic activities of 2-chloroethyl-3-sarcosinamide-1-nitrosourea. Investigational 2-Methoxyestradiol Digitoxin may decrease the cardiotoxic activities of 2-Methoxyestradiol. Investigational 3-Methoxybenzamide Digitoxin may decrease the cardiotoxic activities of 3-Methoxybenzamide. Experimental 3,3'-diindolylmethane Digitoxin may decrease the cardiotoxic activities of 3,3'-diindolylmethane. Investigational 3,4-Dihydroxybenzoic Acid Digitoxin may decrease the cardiotoxic activities of 3,4-Dihydroxybenzoic Acid. Experimental 6-O-benzylguanine Digitoxin may decrease the cardiotoxic activities of 6-O-benzylguanine. Investigational 7-Hydroxystaurosporine Digitoxin may decrease the cardiotoxic activities of 7-Hydroxystaurosporine. Experimental 8-azaguanine Digitoxin may decrease the cardiotoxic activities of 8-azaguanine. Experimental 9-aminocamptothecin Digitoxin may decrease the cardiotoxic activities of 9-aminocamptothecin. Investigational Abiraterone Digitoxin may decrease the cardiotoxic activities of Abiraterone. Approved Acebutolol Acebutolol may increase the bradycardic activities of Digitoxin. Approved Acetaminophen The serum concentration of Digitoxin can be increased when it is combined with Acetaminophen. Approved Aclarubicin Digitoxin may decrease the cardiotoxic activities of Aclarubicin. Investigational Acridine Carboxamide Digitoxin may decrease the cardiotoxic activities of Acridine Carboxamide. Investigational Acteoside Digitoxin may decrease the cardiotoxic activities of Acteoside. Investigational Afatinib Digitoxin may decrease the cardiotoxic activities of Afatinib. Approved Afimoxifene Digitoxin may decrease the cardiotoxic activities of Afimoxifene. Investigational Alatrofloxacin Digitoxin may decrease the cardiotoxic activities of Alatrofloxacin. Withdrawn Albendazole Digitoxin may decrease the cardiotoxic activities of Albendazole. Approved, Vet Approved Alcuronium Alcuronium may increase the arrhythmogenic activities of Digitoxin. Experimental Aldesleukin Digitoxin may decrease the cardiotoxic activities of Aldesleukin. Approved Aldosterone The serum concentration of Digitoxin can be decreased when it is combined with Aldosterone. Experimental Alectinib The serum concentration of Digitoxin can be increased when it is combined with Alectinib. Approved Alemtuzumab Digitoxin may decrease the cardiotoxic activities of Alemtuzumab. Approved, Investigational Alfentanil The serum concentration of Digitoxin can be increased when it is combined with Alfentanil. Approved, Illicit Alitretinoin Digitoxin may decrease the cardiotoxic activities of Alitretinoin. Approved, Investigational Alprenolol Alprenolol may increase the bradycardic activities of Digitoxin. Approved, Withdrawn Altretamine Digitoxin may decrease the cardiotoxic activities of Altretamine. Approved Alvocidib Digitoxin may decrease the cardiotoxic activities of Alvocidib. Experimental, Investigational Amantadine The serum concentration of Digitoxin can be increased when it is combined with Amantadine. Approved Amikacin The serum concentration of Digitoxin can be decreased when it is combined with Amikacin. Approved, Vet Approved Amiloride The therapeutic efficacy of Digitoxin can be decreased when used in combination with Amiloride. Approved Aminoglutethimide Digitoxin may decrease the cardiotoxic activities of Aminoglutethimide. Approved Aminohippuric acid The serum concentration of Digitoxin can be increased when it is combined with Aminohippuric acid. Approved Aminolevulinic acid Digitoxin may decrease the cardiotoxic activities of Aminolevulinic acid. Approved Amiodarone The serum concentration of Digitoxin can be increased when it is combined with Amiodarone. Approved, Investigational Amitriptyline The serum concentration of Digitoxin can be increased when it is combined with Amitriptyline. Approved Amlodipine The serum concentration of Digitoxin can be increased when it is combined with Amlodipine. Approved Amodiaquine The serum concentration of Digitoxin can be increased when it is combined with Amodiaquine. Approved Amonafide Digitoxin may decrease the cardiotoxic activities of Amonafide. Investigational Amphotericin B The risk or severity of adverse effects can be increased when Amphotericin B is combined with Digitoxin. Approved, Investigational Amprenavir The serum concentration of Digitoxin can be decreased when it is combined with Amprenavir. Approved Amrubicin Digitoxin may decrease the cardiotoxic activities of Amrubicin. Approved, Investigational Amsacrine Digitoxin may decrease the cardiotoxic activities of Amsacrine. Approved Anagrelide Digitoxin may decrease the cardiotoxic activities of Anagrelide. Approved Anastrozole Digitoxin may decrease the cardiotoxic activities of Anastrozole. Approved, Investigational Anecortave Digitoxin may decrease the cardiotoxic activities of Anecortave. Investigational annamycin Digitoxin may decrease the cardiotoxic activities of annamycin. Investigational AP 12009 Digitoxin may decrease the cardiotoxic activities of AP 12009. Investigational AP24534 Digitoxin may decrease the cardiotoxic activities of AP24534. Investigational Apaziquone Digitoxin may decrease the cardiotoxic activities of Apaziquone. Investigational Apramycin The serum concentration of Digitoxin can be decreased when it is combined with Apramycin. Experimental, Vet Approved Aprepitant The serum concentration of Digitoxin can be increased when it is combined with Aprepitant. Approved, Investigational Arbekacin The serum concentration of Digitoxin can be decreased when it is combined with Arbekacin. Approved Arotinoid acid Digitoxin may decrease the cardiotoxic activities of TTNPB. Experimental Arotinolol Arotinolol may increase the bradycardic activities of Digitoxin. Approved Arsanilic acid Digitoxin may decrease the cardiotoxic activities of Arsanilic acid. Experimental, Vet Approved Arsenic trioxide Digitoxin may decrease the cardiotoxic activities of Arsenic trioxide. Approved, Investigational Asparaginase Digitoxin may decrease the cardiotoxic activities of Asparaginase. Approved Astemizole The serum concentration of Digitoxin can be increased when it is combined with Astemizole. Approved, Withdrawn Atazanavir The metabolism of Digitoxin can be decreased when combined with Atazanavir. Approved, Investigational Atenolol The serum concentration of Digitoxin can be increased when it is combined with Atenolol. Approved Atomoxetine The metabolism of Digitoxin can be decreased when combined with Atomoxetine. Approved Atorvastatin The serum concentration of Digitoxin can be increased when it is combined with Atorvastatin. Approved Atracurium Atracurium may increase the arrhythmogenic activities of Digitoxin. Experimental Atracurium besylate Atracurium besylate may increase the arrhythmogenic activities of Digitoxin. Approved Axitinib Digitoxin may decrease the cardiotoxic activities of Axitinib. Approved, Investigational Azacitidine Digitoxin may decrease the cardiotoxic activities of Azacitidine. Approved, Investigational Azathioprine Digitoxin may decrease the cardiotoxic activities of Azathioprine. Approved Azelaic Acid Digitoxin may decrease the cardiotoxic activities of Azelaic Acid. Approved Azelastine The serum concentration of Digitoxin can be increased when it is combined with Azelastine. Approved Azithromycin The serum concentration of Digitoxin can be increased when it is combined with Azithromycin. Approved Balsalazide The serum concentration of Digitoxin can be decreased when it is combined with Balsalazide. Approved, Investigational Batimastat Digitoxin may decrease the cardiotoxic activities of Batimastat. Experimental Befunolol Befunolol may increase the bradycardic activities of Digitoxin. Experimental Bekanamycin The serum concentration of Digitoxin can be decreased when it is combined with Bekanamycin. Experimental Belinostat Digitoxin may decrease the cardiotoxic activities of Belinostat. Approved, Investigational Belotecan Digitoxin may decrease the cardiotoxic activities of Belotecan. Investigational Bendamustine Digitoxin may decrease the cardiotoxic activities of Bendamustine. Approved, Investigational Bendroflumethiazide The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Digitoxin. Approved Benzocaine The serum concentration of Digitoxin can be increased when it is combined with Benzocaine. Approved Bepridil The serum concentration of Digitoxin can be increased when it is combined with Bepridil. Approved, Withdrawn Besifloxacin Digitoxin may decrease the cardiotoxic activities of Besifloxacin. Approved Betaxolol Betaxolol may increase the bradycardic activities of Digitoxin. Approved Bevacizumab Digitoxin may decrease the cardiotoxic activities of Bevacizumab. Approved, Investigational Bevantolol Bevantolol may increase the bradycardic activities of Digitoxin. Approved Bexarotene Digitoxin may decrease the cardiotoxic activities of Bexarotene. Approved, Investigational Bicalutamide Digitoxin may decrease the cardiotoxic activities of Bicalutamide. Approved Binetrakin Digitoxin may decrease the cardiotoxic activities of Binetrakin. Investigational Biperiden The serum concentration of Digitoxin can be increased when it is combined with Biperiden. Approved Bisoprolol Bisoprolol may increase the bradycardic activities of Digitoxin. Approved Bizelesin Digitoxin may decrease the cardiotoxic activities of Bizelesin. Investigational Bleomycin Digitoxin may decrease the cardiotoxic activities of Bleomycin. Approved Blinatumomab Digitoxin may decrease the cardiotoxic activities of Blinatumomab. Approved Boceprevir The metabolism of Digitoxin can be decreased when combined with Boceprevir. Withdrawn Bopindolol Bopindolol may increase the bradycardic activities of Digitoxin. Approved Bortezomib Digitoxin may decrease the cardiotoxic activities of Bortezomib. Approved, Investigational Bosentan The serum concentration of Digitoxin can be decreased when it is combined with Bosentan. Approved, Investigational Bosutinib Digitoxin may decrease the cardiotoxic activities of Bosutinib. Approved Brentuximab vedotin Digitoxin may decrease the cardiotoxic activities of Brentuximab vedotin. Approved Bromocriptine The serum concentration of Digitoxin can be increased when it is combined with Bromocriptine. Approved, Investigational Broxuridine Digitoxin may decrease the cardiotoxic activities of Broxuridine. Investigational Bryostatin 1 Digitoxin may decrease the cardiotoxic activities of Bryostatin 1. Investigational BSI-201 Digitoxin may decrease the cardiotoxic activities of BSI-201. Investigational Bucindolol Bucindolol may increase the bradycardic activities of Digitoxin. Investigational Bufuralol Bufuralol may increase the bradycardic activities of Digitoxin. Experimental, Investigational Bumetanide The risk or severity of adverse effects can be increased when Bumetanide is combined with Digitoxin. Approved Bupranolol Bupranolol may increase the bradycardic activities of Digitoxin. Approved Buprenorphine The serum concentration of Digitoxin can be increased when it is combined with Buprenorphine. Approved, Illicit, Investigational, Vet Approved Buspirone The serum concentration of Digitoxin can be increased when it is combined with Buspirone. Approved, Investigational Busulfan Digitoxin may decrease the cardiotoxic activities of Busulfan. Approved, Investigational Buthionine Sulfoximine Digitoxin may decrease the cardiotoxic activities of Buthionine Sulfoximine. Investigational Cabazitaxel Digitoxin may decrease the cardiotoxic activities of Cabazitaxel. Approved Cabergoline Digitoxin may decrease the cardiotoxic activities of Cabergoline. Approved Cabozantinib Digitoxin may decrease the cardiotoxic activities of Cabozantinib. Approved Caffeine The serum concentration of Digitoxin can be increased when it is combined with Caffeine. Approved Calcidiol Calcidiol may increase the arrhythmogenic activities of Digitoxin. Approved, Nutraceutical Calcipotriol Digitoxin may decrease the cardiotoxic activities of Calcipotriol. Approved Calcium Calcium may increase the arrhythmogenic activities of Digitoxin. Nutraceutical Calcium Acetate Calcium Acetate may increase the arrhythmogenic activities of Digitoxin. Approved Calcium Carbonate Calcium Carbonate may increase the arrhythmogenic activities of Digitoxin. Approved Calcium Citrate Calcium Citrate may increase the arrhythmogenic activities of Digitoxin. Approved Calcium glubionate Calcium glubionate may increase the arrhythmogenic activities of Digitoxin. Approved Calcium Gluceptate Calcium Gluceptate may increase the arrhythmogenic activities of Digitoxin. Approved Calcium gluconate Calcium gluconate may increase the arrhythmogenic activities of Digitoxin. Approved, Vet Approved Calcium lactate Calcium lactate may increase the arrhythmogenic activities of Digitoxin. Approved, Experimental, Vet Approved Calcium lactate gluconate Calcium lactate gluconate may increase the arrhythmogenic activities of Digitoxin. Experimental Calcium laevulate Calcium laevulate may increase the arrhythmogenic activities of Digitoxin. Experimental Calcium pangamate Calcium pangamate may increase the arrhythmogenic activities of Digitoxin. Experimental Calcium Phosphate Calcium Phosphate may increase the arrhythmogenic activities of Digitoxin. Approved Camptothecin Digitoxin may decrease the cardiotoxic activities of Camptothecin. Experimental Canagliflozin The serum concentration of Digitoxin can be increased when it is combined with Canagliflozin. Approved Candesartan The serum concentration of Digitoxin can be increased when it is combined with Candesartan. Approved Canertinib Digitoxin may decrease the cardiotoxic activities of Canertinib. Investigational Capecitabine Digitoxin may decrease the cardiotoxic activities of Capecitabine. Approved, Investigational Captopril The serum concentration of Digitoxin can be increased when it is combined with Captopril. Approved Carbamazepine The metabolism of Digitoxin can be increased when combined with Carbamazepine. Approved, Investigational Carbimazole The serum concentration of Digitoxin can be increased when it is combined with Carbimazole. Approved Carbomycin The serum concentration of Digitoxin can be increased when it is combined with Carbomycin. Vet Approved Carboplatin Digitoxin may decrease the cardiotoxic activities of Carboplatin. Approved Carboquone Digitoxin may decrease the cardiotoxic activities of Carboquone. Experimental Carboxyamidotriazole Digitoxin may decrease the cardiotoxic activities of Carboxyamidotriazole. Investigational Carfilzomib Digitoxin may decrease the cardiotoxic activities of Carfilzomib. Approved Carmofur Digitoxin may decrease the cardiotoxic activities of Carmofur. Withdrawn Carmustine Digitoxin may decrease the cardiotoxic activities of Carmustine. Approved Carteolol Carteolol may increase the bradycardic activities of Digitoxin. Approved Carvedilol The serum concentration of Digitoxin can be increased when it is combined with Carvedilol. Approved, Investigational Casein Casein may increase the arrhythmogenic activities of Digitoxin. Approved Caspofungin The serum concentration of Digitoxin can be increased when it is combined with Caspofungin. Approved Catumaxomab Digitoxin may decrease the cardiotoxic activities of Catumaxomab. Investigational Cediranib Digitoxin may decrease the cardiotoxic activities of Cediranib. Investigational Celiprolol Celiprolol may increase the bradycardic activities of Digitoxin. Approved, Investigational Ceritinib The serum concentration of Digitoxin can be increased when it is combined with Ceritinib. Approved Cetuximab Digitoxin may decrease the cardiotoxic activities of Cetuximab. Approved Chlorambucil Digitoxin may decrease the cardiotoxic activities of Chlorambucil. Approved Chloroquine The serum concentration of Digitoxin can be increased when it is combined with Chloroquine. Approved, Vet Approved Chlorothiazide The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Digitoxin. Approved, Vet Approved Chlorotrianisene Digitoxin may decrease the cardiotoxic activities of Chlorotrianisene. Withdrawn Chlorpromazine The serum concentration of Digitoxin can be increased when it is combined with Chlorpromazine. Approved, Vet Approved Chlorpropamide The serum concentration of Digitoxin can be increased when it is combined with Chlorpropamide. Approved Chlorprothixene The serum concentration of Digitoxin can be increased when it is combined with Chlorprothixene. Approved, Withdrawn Chlorthalidone The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Digitoxin. Approved Cholesterol The serum concentration of Digitoxin can be increased when it is combined with Cholesterol. Experimental Cholestyramine Cholestyramine can cause a decrease in the absorption of Digitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Cholic Acid The serum concentration of Digitoxin can be decreased when it is combined with Cholic Acid. Approved Cilazapril The serum concentration of Digitoxin can be increased when it is combined with Cilazapril. Approved Cimetidine The serum concentration of Digitoxin can be decreased when it is combined with Cimetidine. Approved Cinoxacin Digitoxin may decrease the cardiotoxic activities of Cinoxacin. Approved, Withdrawn Ciprofloxacin Digitoxin may decrease the cardiotoxic activities of Ciprofloxacin. Approved, Investigational Cisatracurium Cisatracurium may increase the arrhythmogenic activities of Digitoxin. Experimental Cisatracurium besylate Cisatracurium besylate may increase the arrhythmogenic activities of Digitoxin. Approved Cisplatin Digitoxin may decrease the cardiotoxic activities of Cisplatin. Approved Citalopram The serum concentration of Digitoxin can be increased when it is combined with Citalopram. Approved Cladribine Digitoxin may decrease the cardiotoxic activities of Cladribine. Approved, Investigational Clarithromycin The metabolism of Digitoxin can be decreased when combined with Clarithromycin. Approved Clemastine The metabolism of Digitoxin can be decreased when combined with Clemastine. Approved Clofarabine Digitoxin may decrease the cardiotoxic activities of Clofarabine. Approved, Investigational Clofazimine The serum concentration of Digitoxin can be increased when it is combined with Clofazimine. Approved, Investigational Clomipramine The serum concentration of Digitoxin can be increased when it is combined with Clomipramine. Approved, Vet Approved Clonidine Clonidine may increase the atrioventricular blocking (AV block) activities of Digitoxin. Approved Cloranolol Cloranolol may increase the bradycardic activities of Digitoxin. Experimental Clotrimazole The metabolism of Digitoxin can be decreased when combined with Clotrimazole. Approved, Vet Approved Cobicistat The metabolism of Digitoxin can be decreased when combined with Cobicistat. Approved Colchicine Digitoxin may decrease the cardiotoxic activities of Colchicine. Approved Colesevelam Colesevelam can cause a decrease in the absorption of Digitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colestipol Colestipol can cause a decrease in the absorption of Digitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colforsin The serum concentration of Digitoxin can be increased when it is combined with Colforsin. Experimental Combretastatin Digitoxin may decrease the cardiotoxic activities of Combretastatin. Investigational Conivaptan The serum concentration of Digitoxin can be increased when it is combined with Conivaptan. Approved, Investigational Cordycepin Digitoxin may decrease the cardiotoxic activities of Cordycepin. Investigational Coumermycin A1 Digitoxin may decrease the cardiotoxic activities of Coumermycin A1. Experimental Crenolanib Digitoxin may decrease the cardiotoxic activities of Crenolanib. Investigational Crizotinib Digitoxin may decrease the cardiotoxic activities of Crizotinib. Approved Curcumin Digitoxin may decrease the cardiotoxic activities of Curcumin. Investigational Cyclopenthiazide The risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Digitoxin. Experimental Cyclophosphamide Digitoxin may decrease the cardiotoxic activities of Cyclophosphamide. Approved, Investigational Cyclosporine The metabolism of Digitoxin can be decreased when combined with Cyclosporine. Approved, Investigational, Vet Approved Cyproterone acetate Digitoxin may decrease the cardiotoxic activities of Cyproterone acetate. Approved, Investigational Cytarabine Digitoxin may decrease the cardiotoxic activities of Cytarabine. Approved, Investigational Dabrafenib The serum concentration of Digitoxin can be decreased when it is combined with Dabrafenib. Approved Dacarbazine Digitoxin may decrease the cardiotoxic activities of Dacarbazine. Approved, Investigational Daclatasvir The serum concentration of Digitoxin can be increased when it is combined with Daclatasvir. Approved Dactinomycin Digitoxin may decrease the cardiotoxic activities of Dactinomycin. Approved Daratumumab Digitoxin may decrease the cardiotoxic activities of Daratumumab. Approved Darunavir The metabolism of Digitoxin can be decreased when combined with Darunavir. Approved Dasatinib The serum concentration of Digitoxin can be increased when it is combined with Dasatinib. Approved, Investigational Daunorubicin Digitoxin may decrease the cardiotoxic activities of Daunorubicin. Approved Decamethonium Decamethonium may increase the arrhythmogenic activities of Digitoxin. Approved Decitabine Digitoxin may decrease the cardiotoxic activities of Decitabine. Approved, Investigational Deferasirox The serum concentration of Digitoxin can be decreased when it is combined with Deferasirox. Approved, Investigational Delavirdine The metabolism of Digitoxin can be decreased when combined with Delavirdine. Approved Demecolcine Digitoxin may decrease the cardiotoxic activities of Demecolcine. Experimental Denileukin diftitox Digitoxin may decrease the cardiotoxic activities of Denileukin diftitox. Approved, Investigational Deoxyspergualin Digitoxin may decrease the cardiotoxic activities of Deoxyspergualin. Investigational Desipramine The serum concentration of Digitoxin can be increased when it is combined with Desipramine. Approved Desloratadine The serum concentration of Digitoxin can be increased when it is combined with Desloratadine. Approved, Investigational Dexamethasone Digitoxin may decrease the cardiotoxic activities of Dexamethasone. Approved, Investigational, Vet Approved Dexrazoxane Digitoxin may decrease the cardiotoxic activities of Dexrazoxane. Approved, Withdrawn Dextromethorphan The serum concentration of Digitoxin can be increased when it is combined with Dextromethorphan. Approved Dianhydrogalactitol Digitoxin may decrease the cardiotoxic activities of Dianhydrogalactitol. Investigational Dibekacin The serum concentration of Digitoxin can be decreased when it is combined with Dibekacin. Experimental Diclofenac The serum concentration of Digitoxin can be increased when it is combined with Diclofenac. Approved, Vet Approved Didox Digitoxin may decrease the cardiotoxic activities of Didox. Investigational Dienogest Digitoxin may decrease the cardiotoxic activities of Dienogest. Approved diethylnorspermine Digitoxin may decrease the cardiotoxic activities of diethylnorspermine. Investigational Diethylstilbestrol Digitoxin may decrease the cardiotoxic activities of Diethylstilbestrol. Approved Digoxin The serum concentration of Digitoxin can be decreased when it is combined with Digoxin. Approved Dihydroergotamine The metabolism of Digitoxin can be decreased when combined with Dihydroergotamine. Approved Dihydrostreptomycin The serum concentration of Digitoxin can be decreased when it is combined with Dihydrostreptomycin. Vet Approved Dihydrotachysterol Dihydrotachysterol may increase the arrhythmogenic activities of Digitoxin. Approved Diltiazem The metabolism of Digitoxin can be decreased when combined with Diltiazem. Approved Dinutuximab Digitoxin may decrease the cardiotoxic activities of Dinutuximab. Approved Dipyridamole The serum concentration of Digitoxin can be increased when it is combined with Dipyridamole. Approved Docetaxel Digitoxin may decrease the cardiotoxic activities of Docetaxel. Approved, Investigational Dolastatin 10 Digitoxin may decrease the cardiotoxic activities of Dolastatin 10. Investigational Domoic Acid Domoic Acid may increase the arrhythmogenic activities of Digitoxin. Experimental Doxacurium chloride Doxacurium chloride may increase the arrhythmogenic activities of Digitoxin. Approved Doxazosin The serum concentration of Digitoxin can be increased when it is combined with Doxazosin. Approved Doxepin The serum concentration of Digitoxin can be increased when it is combined with Doxepin. Approved Doxercalciferol Doxercalciferol may increase the arrhythmogenic activities of Digitoxin. Approved Doxifluridine Digitoxin may decrease the cardiotoxic activities of Doxifluridine. Investigational Doxorubicin Digitoxin may decrease the cardiotoxic activities of Doxorubicin. Approved, Investigational Doxycycline The metabolism of Digitoxin can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Dronabinol The serum concentration of Digitoxin can be increased when it is combined with Dronabinol. Approved, Illicit Dronedarone The metabolism of Digitoxin can be decreased when combined with Dronedarone. Approved Duligotuzumab Digitoxin may decrease the cardiotoxic activities of Duligotuzumab. Investigational Ecabet Digitoxin may decrease the cardiotoxic activities of Ecabet. Approved, Investigational Edrecolomab Digitoxin may decrease the cardiotoxic activities of Edrecolomab. Experimental Edrophonium Edrophonium may increase the atrioventricular blocking (AV block) activities of Digitoxin. Approved Efaproxiral Digitoxin may decrease the cardiotoxic activities of Efaproxiral. Investigational Efatutazone Digitoxin may decrease the cardiotoxic activities of Efatutazone. Investigational Eflornithine Digitoxin may decrease the cardiotoxic activities of Eflornithine. Approved, Withdrawn EG009 Digitoxin may decrease the cardiotoxic activities of EG009. Investigational Elbasvir The serum concentration of Digitoxin can be increased when it is combined with Elbasvir. Approved Elsamitrucin Digitoxin may decrease the cardiotoxic activities of Elsamitrucin. Investigational Enalapril The serum concentration of Digitoxin can be increased when it is combined with Enalapril. Approved, Vet Approved Enasidenib The serum concentration of Digitoxin can be increased when it is combined with Enasidenib. Approved Endostatin Digitoxin may decrease the cardiotoxic activities of Endostatin. Investigational Enoxacin Digitoxin may decrease the cardiotoxic activities of Enoxacin. Approved Enrofloxacin Digitoxin may decrease the cardiotoxic activities of Enrofloxacin. Vet Approved Entinostat Digitoxin may decrease the cardiotoxic activities of Entinostat. Investigational Enzalutamide The serum concentration of Digitoxin can be decreased when it is combined with Enzalutamide. Approved Epanolol Epanolol may increase the bradycardic activities of Digitoxin. Experimental Epigallocatechin Gallate Digitoxin may decrease the cardiotoxic activities of Epigallocatechin Gallate. Investigational Epirubicin Digitoxin may decrease the cardiotoxic activities of Epirubicin. Approved Eplerenone The therapeutic efficacy of Digitoxin can be decreased when used in combination with Eplerenone. Approved Epofolate Digitoxin may decrease the cardiotoxic activities of Epofolate. Investigational Ergocalciferol Ergocalciferol may increase the arrhythmogenic activities of Digitoxin. Approved, Nutraceutical Ergonovine The serum concentration of Digitoxin can be increased when it is combined with Ergonovine. Approved Ergotamine The serum concentration of Digitoxin can be increased when it is combined with Ergotamine. Approved Eribulin Digitoxin may decrease the cardiotoxic activities of Eribulin. Approved, Investigational Erlotinib Digitoxin may decrease the cardiotoxic activities of Erlotinib. Approved, Investigational Erythromycin The metabolism of Digitoxin can be decreased when combined with Erythromycin. Approved, Vet Approved Esmolol Esmolol may increase the bradycardic activities of Digitoxin. Approved Estramustine Digitoxin may decrease the cardiotoxic activities of Estramustine. Approved Estriol The serum concentration of Digitoxin can be decreased when it is combined with Estriol. Approved, Vet Approved Estrone The serum concentration of Digitoxin can be decreased when it is combined with Estrone. Approved Etacrynic acid The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Digitoxin. Approved Etanidazole Digitoxin may decrease the cardiotoxic activities of Etanidazole. Investigational Ethiodized oil Digitoxin may decrease the cardiotoxic activities of Ethiodized oil. Approved Ethyl carbamate Digitoxin may decrease the cardiotoxic activities of Ethyl carbamate. Withdrawn Etoglucid Digitoxin may decrease the cardiotoxic activities of Etoglucid. Experimental Etoposide Digitoxin may decrease the cardiotoxic activities of Etoposide. Approved Etravirine The serum concentration of Digitoxin can be increased when it is combined with Etravirine. Approved Everolimus Digitoxin may decrease the cardiotoxic activities of Everolimus. Approved Exatecan Digitoxin may decrease the cardiotoxic activities of Exatecan. Investigational Exemestane Digitoxin may decrease the cardiotoxic activities of Exemestane. Approved, Investigational exisulind Digitoxin may decrease the cardiotoxic activities of exisulind. Investigational Felodipine The serum concentration of Digitoxin can be increased when it is combined with Felodipine. Approved, Investigational Fenretinide Digitoxin may decrease the cardiotoxic activities of Fenretinide. Investigational Fentanyl The serum concentration of Digitoxin can be increased when it is combined with Fentanyl. Approved, Illicit, Investigational, Vet Approved Fexofenadine The serum concentration of Digitoxin can be increased when it is combined with Fexofenadine. Approved Fiacitabine Digitoxin may decrease the cardiotoxic activities of Fiacitabine. Investigational Fidaxomicin The serum concentration of Digitoxin can be increased when it is combined with Fidaxomicin. Approved Fleroxacin Digitoxin may decrease the cardiotoxic activities of Fleroxacin. Approved Floxuridine Digitoxin may decrease the cardiotoxic activities of Floxuridine. Approved Fluconazole The metabolism of Digitoxin can be decreased when combined with Fluconazole. Approved Fludarabine Digitoxin may decrease the cardiotoxic activities of Fludarabine. Approved Flumequine Digitoxin may decrease the cardiotoxic activities of Flumequine. Withdrawn Fluorouracil Digitoxin may decrease the cardiotoxic activities of Fluorouracil. Approved Fluoxetine The serum concentration of Digitoxin can be increased when it is combined with Fluoxetine. Approved, Vet Approved Flupentixol The serum concentration of Digitoxin can be increased when it is combined with Flupentixol. Approved, Withdrawn Fluphenazine The serum concentration of Digitoxin can be increased when it is combined with Fluphenazine. Approved Flurazepam The serum concentration of Digitoxin can be increased when it is combined with Flurazepam. Approved, Illicit Flutamide Digitoxin may decrease the cardiotoxic activities of Flutamide. Approved Fluvoxamine The metabolism of Digitoxin can be decreased when combined with Fluvoxamine. Approved, Investigational Formestane Digitoxin may decrease the cardiotoxic activities of Formestane. Approved, Investigational, Withdrawn Formycin Digitoxin may decrease the cardiotoxic activities of Formycin. Experimental Fosamprenavir The metabolism of Digitoxin can be decreased when combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Digitoxin can be increased when it is combined with Fosaprepitant. Approved Fosbretabulin Digitoxin may decrease the cardiotoxic activities of Fosbretabulin. Investigational Fosphenytoin The metabolism of Digitoxin can be increased when combined with Fosphenytoin. Approved Fotemustine Digitoxin may decrease the cardiotoxic activities of Fotemustine. Experimental Framycetin The serum concentration of Digitoxin can be decreased when it is combined with Framycetin. Approved Fulvestrant Digitoxin may decrease the cardiotoxic activities of Fulvestrant. Approved, Investigational Fumagillin Digitoxin may decrease the cardiotoxic activities of Fumagillin. Experimental Furosemide The risk or severity of adverse effects can be increased when Furosemide is combined with Digitoxin. Approved, Vet Approved Fusidic Acid The serum concentration of Digitoxin can be increased when it is combined with Fusidic Acid. Approved Gallamine Gallamine may increase the arrhythmogenic activities of Digitoxin. Experimental Gallamine Triethiodide Gallamine Triethiodide may increase the arrhythmogenic activities of Digitoxin. Approved Gallium nitrate Digitoxin may decrease the cardiotoxic activities of Gallium nitrate. Approved, Investigational Garenoxacin Digitoxin may decrease the cardiotoxic activities of Garenoxacin. Investigational Gatifloxacin Digitoxin may decrease the cardiotoxic activities of Gatifloxacin. Approved, Investigational Gefitinib Digitoxin may decrease the cardiotoxic activities of Gefitinib. Approved, Investigational Geldanamycin Digitoxin may decrease the cardiotoxic activities of Geldanamycin. Experimental Gemcitabine Digitoxin may decrease the cardiotoxic activities of Gemcitabine. Approved Gemifloxacin Digitoxin may decrease the cardiotoxic activities of Gemifloxacin. Approved, Investigational Gemtuzumab ozogamicin Digitoxin may decrease the cardiotoxic activities of Gemtuzumab ozogamicin. Approved Geneticin The serum concentration of Digitoxin can be decreased when it is combined with Geneticin. Experimental Genistein Digitoxin may decrease the cardiotoxic activities of Genistein. Investigational Gentamicin The serum concentration of Digitoxin can be decreased when it is combined with Gentamicin. Approved, Vet Approved GENTAMICIN C1A The serum concentration of Digitoxin can be decreased when it is combined with GENTAMICIN C1A. Experimental Ginsenoside C Digitoxin may decrease the cardiotoxic activities of Ginsenoside C. Nutraceutical Glecaprevir The serum concentration of Digitoxin can be increased when it is combined with Glecaprevir. Approved Glyburide The serum concentration of Digitoxin can be increased when it is combined with Glyburide. Approved Glycerin The serum concentration of Digitoxin can be increased when it is combined with Glycerin. Approved, Investigational Goserelin Digitoxin may decrease the cardiotoxic activities of Goserelin. Approved GPX-150 The serum concentration of Digitoxin can be decreased when it is combined with GPX-150. Investigational Gramicidin D The serum concentration of Digitoxin can be increased when it is combined with Gramicidin D. Approved Grepafloxacin Digitoxin may decrease the cardiotoxic activities of Grepafloxacin. Withdrawn GS 0573 Digitoxin may decrease the cardiotoxic activities of GS 0573. Investigational Gusperimus Digitoxin may decrease the cardiotoxic activities of Gusperimus. Investigational Hadacidin Digitoxin may decrease the cardiotoxic activities of Hadacidin. Experimental Halofuginone Digitoxin may decrease the cardiotoxic activities of Halofuginone. Investigational, Vet Approved Haloperidol The serum concentration of Digitoxin can be increased when it is combined with Haloperidol. Approved Hexestrol Digitoxin may decrease the cardiotoxic activities of Hexestrol. Withdrawn Hydrochlorothiazide The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digitoxin. Approved, Vet Approved Hydrocortisone The serum concentration of Digitoxin can be increased when it is combined with Hydrocortisone. Approved, Vet Approved Hydroflumethiazide The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Digitoxin. Approved Hydroxychloroquine The serum concentration of Digitoxin can be increased when it is combined with Hydroxychloroquine. Approved Hydroxyprogesterone caproate Digitoxin may decrease the cardiotoxic activities of Hydroxyprogesterone caproate. Approved Hydroxyurea Digitoxin may decrease the cardiotoxic activities of Hydroxyurea. Approved Hygromycin B The serum concentration of Digitoxin can be decreased when it is combined with Hygromycin B. Vet Approved Hypericin Digitoxin may decrease the cardiotoxic activities of Hypericin. Investigational Ibrutinib Digitoxin may decrease the cardiotoxic activities of Ibrutinib. Approved Idarubicin Digitoxin may decrease the cardiotoxic activities of Idarubicin. Approved Idelalisib The serum concentration of Digitoxin can be increased when it is combined with Idelalisib. Approved Ifosfamide Digitoxin may decrease the cardiotoxic activities of Ifosfamide. Approved Imatinib Digitoxin may decrease the cardiotoxic activities of Imatinib. Approved Imipramine The serum concentration of Digitoxin can be increased when it is combined with Imipramine. Approved Imiquimod Digitoxin may decrease the cardiotoxic activities of Imiquimod. Approved, Investigational Indapamide The risk or severity of adverse effects can be increased when Indapamide is combined with Digitoxin. Approved Indenolol Indenolol may increase the bradycardic activities of Digitoxin. Withdrawn Indinavir The metabolism of Digitoxin can be decreased when combined with Indinavir. Approved Indirubin Digitoxin may decrease the cardiotoxic activities of Indirubin. Investigational Indole-3-carbinol Digitoxin may decrease the cardiotoxic activities of Indole-3-carbinol. Investigational Indomethacin The serum concentration of Digitoxin can be increased when it is combined with Indomethacin. Approved, Investigational Infigratinib Digitoxin may decrease the cardiotoxic activities of Infigratinib. Investigational Iniparib Digitoxin may decrease the cardiotoxic activities of Iniparib. Experimental INNO-206 The serum concentration of Digitoxin can be decreased when it is combined with INNO-206. Investigational Interferon beta-1a Digitoxin may decrease the cardiotoxic activities of Interferon beta-1a. Approved, Investigational Iobenguane Digitoxin may decrease the cardiotoxic activities of Iobenguane. Approved Ipilimumab Digitoxin may decrease the cardiotoxic activities of Ipilimumab. Approved Irinotecan Digitoxin may decrease the cardiotoxic activities of Irinotecan. Approved, Investigational Irofulven Digitoxin may decrease the cardiotoxic activities of Irofulven. Investigational Irsogladine Digitoxin may decrease the cardiotoxic activities of Irsogladine. Investigational Isavuconazonium The metabolism of Digitoxin can be decreased when combined with Isavuconazonium. Approved, Investigational Isepamicin The serum concentration of Digitoxin can be decreased when it is combined with Isepamicin. Experimental Isosorbide Digitoxin may decrease the cardiotoxic activities of Isosorbide. Approved Isradipine The metabolism of Digitoxin can be decreased when combined with Isradipine. Approved Itraconazole The serum concentration of Digitoxin can be increased when it is combined with Itraconazole. Approved, Investigational Ivacaftor The serum concentration of Digitoxin can be increased when it is combined with Ivacaftor. Approved Ivermectin The serum concentration of Digitoxin can be increased when it is combined with Ivermectin. Approved, Vet Approved Ixabepilone Digitoxin may decrease the cardiotoxic activities of Ixabepilone. Approved, Investigational Ixazomib Digitoxin may decrease the cardiotoxic activities of Ixazomib. Approved Josamycin The serum concentration of Digitoxin can be increased when it is combined with Josamycin. Approved Kanamycin The serum concentration of Digitoxin can be decreased when it is combined with Kanamycin. Approved, Vet Approved Kaolin The serum concentration of Digitoxin can be decreased when it is combined with Kaolin. Approved Ketamine The serum concentration of Digitoxin can be increased when it is combined with Ketamine. Approved, Vet Approved Ketoconazole The metabolism of Digitoxin can be decreased when combined with Ketoconazole. Approved, Investigational Kitasamycin The serum concentration of Digitoxin can be increased when it is combined with Kitasamycin. Experimental KOS-1584 Digitoxin may decrease the cardiotoxic activities of KOS-1584. Investigational KRN-7000 Digitoxin may decrease the cardiotoxic activities of KRN-7000. Investigational L-alanosine Digitoxin may decrease the cardiotoxic activities of L-alanosine. Investigational Labetalol Labetalol may increase the bradycardic activities of Digitoxin. Approved Landiolol Landiolol may increase the bradycardic activities of Digitoxin. Investigational Lanreotide Digitoxin may decrease the cardiotoxic activities of Lanreotide. Approved Lansoprazole The serum concentration of Digitoxin can be increased when it is combined with Lansoprazole. Approved, Investigational Lapatinib Digitoxin may decrease the cardiotoxic activities of Lapatinib. Approved, Investigational LCL-161 Digitoxin may decrease the cardiotoxic activities of LCL-161. Investigational Leflunomide Digitoxin may decrease the cardiotoxic activities of Leflunomide. Approved, Investigational Lenalidomide Digitoxin may decrease the cardiotoxic activities of Lenalidomide. Approved Lentinan Digitoxin may decrease the cardiotoxic activities of Lentinan. Experimental Lenvatinib Digitoxin may decrease the cardiotoxic activities of Lenvatinib. Approved Letrozole Digitoxin may decrease the cardiotoxic activities of Letrozole. Approved, Investigational Leuprolide Digitoxin may decrease the cardiotoxic activities of Leuprolide. Approved, Investigational Levobunolol Levobunolol may increase the bradycardic activities of Digitoxin. Approved Levofloxacin Digitoxin may decrease the cardiotoxic activities of Levofloxacin. Approved, Investigational Levothyroxine The serum concentration of Digitoxin can be decreased when it is combined with Levothyroxine. Approved Liarozole Digitoxin may decrease the cardiotoxic activities of Liarozole. Investigational Licorice The risk or severity of adverse effects can be increased when Licorice is combined with Digitoxin. Approved Lidocaine The serum concentration of Digitoxin can be increased when it is combined with Lidocaine. Approved, Vet Approved Liothyronine The serum concentration of Digitoxin can be decreased when it is combined with Liothyronine. Approved, Vet Approved Liotrix The serum concentration of Digitoxin can be decreased when it is combined with Liotrix. Approved Lisinopril The serum concentration of Digitoxin can be increased when it is combined with Lisinopril. Approved, Investigational Lomefloxacin Digitoxin may decrease the cardiotoxic activities of Lomefloxacin. Approved Lometrexol Digitoxin may decrease the cardiotoxic activities of Lometrexol. Investigational Lomitapide The serum concentration of Digitoxin can be increased when it is combined with Lomitapide. Approved Lomustine Digitoxin may decrease the cardiotoxic activities of Lomustine. Approved Lonidamine Digitoxin may decrease the cardiotoxic activities of Lonidamine. Approved, Investigational Loperamide The serum concentration of Digitoxin can be increased when it is combined with Loperamide. Approved Lopinavir The metabolism of Digitoxin can be decreased when combined with Lopinavir. Approved Loratadine The serum concentration of Digitoxin can be increased when it is combined with Loratadine. Approved Losartan The serum concentration of Digitoxin can be increased when it is combined with Losartan. Approved Lovastatin The metabolism of Digitoxin can be decreased when combined with Lovastatin. Approved, Investigational Luliconazole The serum concentration of Digitoxin can be increased when it is combined with Luliconazole. Approved Lumacaftor The serum concentration of Digitoxin can be decreased when it is combined with Lumacaftor. Approved Lurtotecan Digitoxin may decrease the cardiotoxic activities of Lurtotecan. Investigational Lycopene Digitoxin may decrease the cardiotoxic activities of Lycopene. Approved Mafosfamide Digitoxin may decrease the cardiotoxic activities of Mafosfamide. Investigational Mannosulfan Digitoxin may decrease the cardiotoxic activities of Mannosulfan. Experimental Maprotiline The serum concentration of Digitoxin can be increased when it is combined with Maprotiline. Approved Masitinib Digitoxin may decrease the cardiotoxic activities of Masitinib. Vet Approved Masoprocol Digitoxin may decrease the cardiotoxic activities of Masoprocol. Approved Maxacalcitol Digitoxin may decrease the cardiotoxic activities of Maxacalcitol. Approved Mebendazole Digitoxin may decrease the cardiotoxic activities of Mebendazole. Approved, Vet Approved Mechlorethamine Digitoxin may decrease the cardiotoxic activities of Mechlorethamine. Approved Medrogestone Digitoxin may decrease the cardiotoxic activities of Medrogestone. Approved Medroxyprogesterone acetate Digitoxin may decrease the cardiotoxic activities of Medroxyprogesterone acetate. Approved, Investigational Mefloquine The serum concentration of Digitoxin can be increased when it is combined with Mefloquine. Approved Megestrol acetate Digitoxin may decrease the cardiotoxic activities of Megestrol acetate. Approved, Vet Approved Melphalan Digitoxin may decrease the cardiotoxic activities of Melphalan. Approved Mepindolol Mepindolol may increase the bradycardic activities of Digitoxin. Experimental Meprobamate The serum concentration of Digitoxin can be increased when it is combined with Meprobamate. Approved, Illicit Mequinol Digitoxin may decrease the cardiotoxic activities of Mequinol. Approved Mercaptopurine Digitoxin may decrease the cardiotoxic activities of Mercaptopurine. Approved Merestinib Digitoxin may decrease the cardiotoxic activities of Merestinib. Investigational Mesalazine The serum concentration of Digitoxin can be decreased when it is combined with Mesalazine. Approved Methadone The serum concentration of Digitoxin can be increased when it is combined with Methadone. Approved Methimazole The serum concentration of Digitoxin can be increased when it is combined with Methimazole. Approved Methotrexate Digitoxin may decrease the cardiotoxic activities of Methotrexate. Approved Methyclothiazide The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Digitoxin. Approved Methyl aminolevulinate Digitoxin may decrease the cardiotoxic activities of Methyl aminolevulinate. Approved Methylprednisolone Digitoxin may decrease the cardiotoxic activities of Methylprednisolone. Approved, Vet Approved Methylselenocysteine Digitoxin may decrease the cardiotoxic activities of Methylselenocysteine. Investigational Methyltestosterone Digitoxin may decrease the cardiotoxic activities of Methyltestosterone. Approved Methylthiouracil The serum concentration of Digitoxin can be increased when it is combined with Methylthiouracil. Experimental Metipranolol Metipranolol may increase the bradycardic activities of Digitoxin. Approved Metocurine Metocurine may increase the arrhythmogenic activities of Digitoxin. Approved Metocurine Iodide Metocurine Iodide may increase the arrhythmogenic activities of Digitoxin. Withdrawn Metolazone The risk or severity of adverse effects can be increased when Metolazone is combined with Digitoxin. Approved Metoprine Digitoxin may decrease the cardiotoxic activities of Metoprine. Experimental Metoprolol The serum concentration of Digitoxin can be increased when it is combined with Metoprolol. Approved, Investigational Metrizamide The serum concentration of Digitoxin can be decreased when it is combined with Metrizamide. Approved Mibefradil The serum concentration of Digitoxin can be increased when it is combined with Mibefradil. Withdrawn Miconazole The serum concentration of Digitoxin can be increased when it is combined with Miconazole. Approved, Investigational, Vet Approved Micronomicin The serum concentration of Digitoxin can be decreased when it is combined with Micronomicin. Experimental Midazolam The serum concentration of Digitoxin can be decreased when it is combined with Midazolam. Approved, Illicit Midodrine Digitoxin may increase the bradycardic activities of Midodrine. Approved Midostaurin Digitoxin may decrease the cardiotoxic activities of Midostaurin. Approved Mifepristone The serum concentration of Digitoxin can be increased when it is combined with Mifepristone. Approved, Investigational Miltefosine Digitoxin may decrease the cardiotoxic activities of Miltefosine. Approved Misonidazole Digitoxin may decrease the cardiotoxic activities of Misonidazole. Investigational Mitobronitol Digitoxin may decrease the cardiotoxic activities of Mitobronitol. Experimental Mitoguazone Digitoxin may decrease the cardiotoxic activities of Mitoguazone. Investigational Mitolactol Digitoxin may decrease the cardiotoxic activities of Mitolactol. Investigational Mitomycin Digitoxin may decrease the cardiotoxic activities of Mitomycin. Approved Mitotane The serum concentration of Digitoxin can be decreased when it is combined with Mitotane. Approved Mitoxantrone Digitoxin may decrease the cardiotoxic activities of Mitoxantrone. Approved, Investigational Mivacurium Mivacurium may increase the arrhythmogenic activities of Digitoxin. Approved Mizoribine Digitoxin may decrease the cardiotoxic activities of Mizoribine. Investigational MLN576 Digitoxin may decrease the cardiotoxic activities of MLN576. Investigational Molgramostim Digitoxin may decrease the cardiotoxic activities of Molgramostim. Investigational Morphine The serum concentration of Digitoxin can be increased when it is combined with Morphine. Approved, Investigational motexafin gadolinium Digitoxin may decrease the cardiotoxic activities of motexafin gadolinium. Investigational Moxifloxacin Digitoxin may decrease the cardiotoxic activities of Moxifloxacin. Approved, Investigational Mycophenolic acid Digitoxin may decrease the cardiotoxic activities of Mycophenolic acid. Approved Nadifloxacin Digitoxin may decrease the cardiotoxic activities of Nadifloxacin. Investigational Nadolol Nadolol may increase the bradycardic activities of Digitoxin. Approved Nalidixic Acid Digitoxin may decrease the cardiotoxic activities of Nalidixic Acid. Approved Naltrexone The serum concentration of Digitoxin can be increased when it is combined with Naltrexone. Approved, Investigational, Vet Approved Namitecan Digitoxin may decrease the cardiotoxic activities of Namitecan. Investigational Naringenin The serum concentration of Digitoxin can be increased when it is combined with Naringenin. Experimental Navitoclax Digitoxin may decrease the cardiotoxic activities of Navitoclax. Investigational Neamine The serum concentration of Digitoxin can be decreased when it is combined with Neamine. Experimental Nebularine Digitoxin may decrease the cardiotoxic activities of Nebularine. Experimental Necitumumab Digitoxin may decrease the cardiotoxic activities of Necitumumab. Approved Nedaplatin Digitoxin may decrease the cardiotoxic activities of Nedaplatin. Approved Nefazodone The metabolism of Digitoxin can be decreased when combined with Nefazodone. Approved, Withdrawn Nelarabine Digitoxin may decrease the cardiotoxic activities of Nelarabine. Approved, Investigational Nelfinavir The metabolism of Digitoxin can be decreased when combined with Nelfinavir. Approved Neomycin The serum concentration of Digitoxin can be decreased when it is combined with Neomycin. Approved, Vet Approved Neosaxitoxin Neosaxitoxin may increase the arrhythmogenic activities of Digitoxin. Investigational Neostigmine The serum concentration of Digitoxin can be increased when it is combined with Neostigmine. Approved, Vet Approved Netilmicin The serum concentration of Digitoxin can be decreased when it is combined with Netilmicin. Approved Netupitant The serum concentration of Digitoxin can be increased when it is combined with Netupitant. Approved Nevirapine The metabolism of Digitoxin can be increased when combined with Nevirapine. Approved Nicardipine The serum concentration of Digitoxin can be increased when it is combined with Nicardipine. Approved Nifedipine The serum concentration of Digitoxin can be decreased when it is combined with Nifedipine. Approved Niguldipine Digitoxin may decrease the cardiotoxic activities of Niguldipine. Experimental Nilotinib Digitoxin may decrease the cardiotoxic activities of Nilotinib. Approved, Investigational Nilutamide Digitoxin may decrease the cardiotoxic activities of Nilutamide. Approved Nimustine Digitoxin may decrease the cardiotoxic activities of Nimustine. Investigational Nintedanib Digitoxin may decrease the cardiotoxic activities of Nintedanib. Approved Niraparib Digitoxin may decrease the cardiotoxic activities of Niraparib. Approved, Investigational Nisoldipine The serum concentration of Digitoxin can be increased when it is combined with Nisoldipine. Approved Nitrazepam The serum concentration of Digitoxin can be increased when it is combined with Nitrazepam. Approved Nitrendipine The serum concentration of Digitoxin can be increased when it is combined with Nitrendipine. Approved Nivolumab Digitoxin may decrease the cardiotoxic activities of Nivolumab. Approved nocodazole Digitoxin may decrease the cardiotoxic activities of nocodazole. Experimental Nolatrexed Digitoxin may decrease the cardiotoxic activities of Nolatrexed. Investigational Norethisterone The serum concentration of Digitoxin can be decreased when it is combined with Norethisterone. Approved Norfloxacin Digitoxin may decrease the cardiotoxic activities of Norfloxacin. Approved Obinutuzumab Digitoxin may decrease the cardiotoxic activities of Obinutuzumab. Approved Oblimersen Digitoxin may decrease the cardiotoxic activities of Oblimersen. Experimental OBP-801 Digitoxin may decrease the cardiotoxic activities of OBP-801. Investigational Octreotide Digitoxin may decrease the cardiotoxic activities of Octreotide. Approved, Investigational Ofatumumab Digitoxin may decrease the cardiotoxic activities of Ofatumumab. Approved Ofloxacin Digitoxin may decrease the cardiotoxic activities of Ofloxacin. Approved Oglufanide Digitoxin may decrease the cardiotoxic activities of Oglufanide. Investigational Olaparib Digitoxin may decrease the cardiotoxic activities of Olaparib. Approved Oleandomycin The serum concentration of Digitoxin can be increased when it is combined with Oleandomycin. Vet Approved Olsalazine The serum concentration of Digitoxin can be decreased when it is combined with Olsalazine. Approved Oltipraz Digitoxin may decrease the cardiotoxic activities of Oltipraz. Investigational Omacetaxine mepesuccinate Digitoxin may decrease the cardiotoxic activities of Omacetaxine mepesuccinate. Approved Omeprazole The serum concentration of Digitoxin can be increased when it is combined with Omeprazole. Approved, Investigational, Vet Approved Onapristone Digitoxin may decrease the cardiotoxic activities of Onapristone. Investigational Oprelvekin Digitoxin may decrease the cardiotoxic activities of Oprelvekin. Approved, Investigational Osimertinib The serum concentration of Digitoxin can be increased when it is combined with Osimertinib. Approved Oxaliplatin Digitoxin may decrease the cardiotoxic activities of Oxaliplatin. Approved, Investigational Oxolinic acid Digitoxin may decrease the cardiotoxic activities of Oxolinic acid. Experimental Oxprenolol Oxprenolol may increase the bradycardic activities of Digitoxin. Approved P-Nitrophenol The serum concentration of Digitoxin can be increased when it is combined with P-Nitrophenol. Experimental Paclitaxel Digitoxin may decrease the cardiotoxic activities of Paclitaxel. Approved, Vet Approved Paclitaxel poliglumex Digitoxin may decrease the cardiotoxic activities of Paclitaxel poliglumex. Experimental Palbociclib The serum concentration of Digitoxin can be increased when it is combined with Palbociclib. Approved Palifosfamide Digitoxin may decrease the cardiotoxic activities of Palifosfamide. Investigational Palmitic Acid The serum concentration of Digitoxin can be increased when it is combined with Palmitic Acid. Experimental Pamidronate Digitoxin may decrease the cardiotoxic activities of Pamidronate. Approved Pancuronium Pancuronium may increase the arrhythmogenic activities of Digitoxin. Approved Panitumumab Digitoxin may decrease the cardiotoxic activities of Panitumumab. Approved, Investigational Panobinostat Digitoxin may decrease the cardiotoxic activities of Panobinostat. Approved, Investigational Pantoprazole The serum concentration of Digitoxin can be increased when it is combined with Pantoprazole. Approved Parathyroid hormone The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Digitoxin. Approved, Investigational Paricalcitol Paricalcitol may increase the arrhythmogenic activities of Digitoxin. Approved, Investigational Paromomycin The serum concentration of Digitoxin can be decreased when it is combined with Paromomycin. Approved, Investigational Paroxetine The serum concentration of Digitoxin can be increased when it is combined with Paroxetine. Approved, Investigational Patupilone Digitoxin may decrease the cardiotoxic activities of Patupilone. Experimental, Investigational Pazopanib Digitoxin may decrease the cardiotoxic activities of Pazopanib. Approved Pazufloxacin Digitoxin may decrease the cardiotoxic activities of Pazufloxacin. Investigational Pefloxacin Digitoxin may decrease the cardiotoxic activities of Pefloxacin. Approved Pegaspargase Digitoxin may decrease the cardiotoxic activities of Pegaspargase. Approved, Investigational Pembrolizumab Digitoxin may decrease the cardiotoxic activities of Pembrolizumab. Approved Pemetrexed Digitoxin may decrease the cardiotoxic activities of Pemetrexed. Approved, Investigational Penbutolol Penbutolol may increase the bradycardic activities of Digitoxin. Approved, Investigational Penclomedine Digitoxin may decrease the cardiotoxic activities of Penclomedine. Investigational Pentobarbital The metabolism of Digitoxin can be increased when combined with Pentobarbital. Approved, Vet Approved Pentostatin Digitoxin may decrease the cardiotoxic activities of Pentostatin. Approved, Investigational Perindopril The serum concentration of Digitoxin can be increased when it is combined with Perindopril. Approved Pertuzumab Digitoxin may decrease the cardiotoxic activities of Pertuzumab. Approved Phenethyl Isothiocyanate Digitoxin may decrease the cardiotoxic activities of Phenethyl Isothiocyanate. Investigational Phenobarbital The metabolism of Digitoxin can be increased when combined with Phenobarbital. Approved Phenylacetic acid Digitoxin may decrease the cardiotoxic activities of Phenylacetic acid. Approved Phenylbutyric acid Digitoxin may decrease the cardiotoxic activities of Phenylbutyric acid. Approved, Investigational Phenytoin The metabolism of Digitoxin can be increased when combined with Phenytoin. Approved, Vet Approved Pibrentasvir The serum concentration of Digitoxin can be increased when it is combined with Pibrentasvir. Approved Pimozide The serum concentration of Digitoxin can be increased when it is combined with Pimozide. Approved Pindolol Pindolol may increase the bradycardic activities of Digitoxin. Approved Pinometostat Digitoxin may decrease the cardiotoxic activities of Pinometostat. Investigational Pipecuronium Pipecuronium may increase the arrhythmogenic activities of Digitoxin. Approved Pipobroman Digitoxin may decrease the cardiotoxic activities of Pipobroman. Approved Pirarubicin Digitoxin may decrease the cardiotoxic activities of Pirarubicin. Investigational Piretanide The risk or severity of adverse effects can be increased when Piretanide is combined with Digitoxin. Experimental Pirfenidone Digitoxin may decrease the cardiotoxic activities of Pirfenidone. Investigational Pirlindole Digitoxin may decrease the cardiotoxic activities of Pirlindole. Approved Pixantrone Digitoxin may decrease the cardiotoxic activities of Pixantrone. Investigational Platelet Activating Factor The serum concentration of Digitoxin can be decreased when it is combined with Platelet Activating Factor. Experimental Plazomicin The serum concentration of Digitoxin can be decreased when it is combined with Plazomicin. Investigational Plevitrexed Digitoxin may decrease the cardiotoxic activities of Plevitrexed. Investigational Plicamycin Digitoxin may decrease the cardiotoxic activities of Plicamycin. Approved, Withdrawn Podofilox Digitoxin may decrease the cardiotoxic activities of Podofilox. Approved Podophyllin Digitoxin may decrease the cardiotoxic activities of Podophyllin. Approved Polythiazide The risk or severity of adverse effects can be increased when Polythiazide is combined with Digitoxin. Approved Pomalidomide Digitoxin may decrease the cardiotoxic activities of Pomalidomide. Approved Ponatinib Digitoxin may decrease the cardiotoxic activities of Ponatinib. Approved Porfimer sodium Digitoxin may decrease the cardiotoxic activities of Porfimer sodium. Approved, Investigational porfiromycin Digitoxin may decrease the cardiotoxic activities of porfiromycin. Investigational Posaconazole The metabolism of Digitoxin can be decreased when combined with Posaconazole. Approved, Investigational, Vet Approved Practolol Practolol may increase the bradycardic activities of Digitoxin. Approved Pralatrexate Digitoxin may decrease the cardiotoxic activities of Pralatrexate. Approved Pravastatin The serum concentration of Digitoxin can be increased when it is combined with Pravastatin. Approved Prazosin The serum concentration of Digitoxin can be increased when it is combined with Prazosin. Approved Prednimustine Digitoxin may decrease the cardiotoxic activities of Prednimustine. Investigational Prednisolone Digitoxin may decrease the cardiotoxic activities of Prednisolone. Approved, Vet Approved Prednisone Digitoxin may decrease the cardiotoxic activities of Prednisone. Approved, Vet Approved Primaquine The serum concentration of Digitoxin can be increased when it is combined with Primaquine. Approved Primidone The metabolism of Digitoxin can be increased when combined with Primidone. Approved, Vet Approved Probenecid The serum concentration of Digitoxin can be increased when it is combined with Probenecid. Approved Procarbazine Digitoxin may decrease the cardiotoxic activities of Procarbazine. Approved Progesterone The serum concentration of Digitoxin can be decreased when it is combined with Progesterone. Approved, Vet Approved Promethazine The serum concentration of Digitoxin can be increased when it is combined with Promethazine. Approved Propafenone The serum concentration of Digitoxin can be increased when it is combined with Propafenone. Approved Propranolol The serum concentration of Digitoxin can be increased when it is combined with Propranolol. Approved, Investigational Propylthiouracil The serum concentration of Digitoxin can be increased when it is combined with Propylthiouracil. Approved Protriptyline The serum concentration of Digitoxin can be increased when it is combined with Protriptyline. Approved Prulifloxacin Digitoxin may decrease the cardiotoxic activities of Prulifloxacin. Investigational Puromycin Digitoxin may decrease the cardiotoxic activities of Puromycin. Experimental Pyrantel Pyrantel may increase the arrhythmogenic activities of Digitoxin. Approved, Vet Approved Pyrazoloacridine Digitoxin may decrease the cardiotoxic activities of Pyrazoloacridine. Investigational Quercetin The serum concentration of Digitoxin can be increased when it is combined with Quercetin. Experimental Quinacrine Digitoxin may decrease the cardiotoxic activities of Quinacrine. Approved Quinethazone The risk or severity of adverse effects can be increased when Quinethazone is combined with Digitoxin. Approved Quinidine The serum concentration of Digitoxin can be increased when it is combined with Quinidine. Approved Quinine The serum concentration of Digitoxin can be increased when it is combined with Quinine. Approved Rabusertib Digitoxin may decrease the cardiotoxic activities of Rabusertib. Investigational Radium Ra 223 Dichloride Digitoxin may decrease the cardiotoxic activities of Radium Ra 223 Dichloride. Approved, Investigational Raltitrexed Digitoxin may decrease the cardiotoxic activities of Raltitrexed. Approved, Investigational Ramucirumab Digitoxin may decrease the cardiotoxic activities of Ramucirumab. Approved, Investigational Ranibizumab Digitoxin may decrease the cardiotoxic activities of Ranibizumab. Approved Ranimustine Digitoxin may decrease the cardiotoxic activities of Ranimustine. Experimental Ranitidine The serum concentration of Digitoxin can be increased when it is combined with Ranitidine. Approved Ranolazine The serum concentration of Digitoxin can be increased when it is combined with Ranolazine. Approved, Investigational Ranpirnase Digitoxin may decrease the cardiotoxic activities of Ranpirnase. Investigational Rapacuronium Rapacuronium may increase the arrhythmogenic activities of Digitoxin. Withdrawn Reboxetine The serum concentration of Digitoxin can be increased when it is combined with Reboxetine. Approved, Investigational Regorafenib Digitoxin may decrease the cardiotoxic activities of Regorafenib. Approved Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Digitoxin. Approved Resveratrol Digitoxin may decrease the cardiotoxic activities of Resveratrol. Experimental, Investigational Rhodamine 6G Digitoxin may decrease the cardiotoxic activities of Rhodamine 6G. Experimental Ribostamycin The serum concentration of Digitoxin can be decreased when it is combined with Ribostamycin. Approved Ridaforolimus Digitoxin may decrease the cardiotoxic activities of Ridaforolimus. Investigational Rifabutin The metabolism of Digitoxin can be increased when combined with Rifabutin. Approved Rifampicin The metabolism of Digitoxin can be increased when combined with Rifampicin. Approved Rifapentine The metabolism of Digitoxin can be increased when combined with Rifapentine. Approved Rilpivirine The serum concentration of Digitoxin can be increased when it is combined with Rilpivirine. Approved Ritonavir The metabolism of Digitoxin can be decreased when combined with Ritonavir. Approved, Investigational Rituximab Digitoxin may decrease the cardiotoxic activities of Rituximab. Approved Rocuronium Rocuronium may increase the arrhythmogenic activities of Digitoxin. Approved Rolapitant The serum concentration of Digitoxin can be increased when it is combined with Rolapitant. Approved Romidepsin Digitoxin may decrease the cardiotoxic activities of Romidepsin. Approved, Investigational Roquinimex Digitoxin may decrease the cardiotoxic activities of Roquinimex. Investigational Rubitecan Digitoxin may decrease the cardiotoxic activities of Rubitecan. Investigational Rucaparib Digitoxin may decrease the cardiotoxic activities of Rucaparib. Approved, Investigational Rufloxacin Digitoxin may decrease the cardiotoxic activities of Rufloxacin. Experimental Ruxolitinib Digitoxin may decrease the cardiotoxic activities of Ruxolitinib. Approved Sabarubicin The serum concentration of Digitoxin can be decreased when it is combined with Sabarubicin. Investigational Salirasib Digitoxin may decrease the cardiotoxic activities of Salirasib. Investigational Saquinavir The metabolism of Digitoxin can be decreased when combined with Saquinavir. Approved, Investigational Saracatinib Digitoxin may decrease the cardiotoxic activities of Saracatinib. Investigational Satraplatin Digitoxin may decrease the cardiotoxic activities of Satraplatin. Investigational Scopolamine The serum concentration of Digitoxin can be increased when it is combined with Scopolamine. Approved Selegiline The serum concentration of Digitoxin can be increased when it is combined with Selegiline. Approved, Investigational, Vet Approved Seliciclib Digitoxin may decrease the cardiotoxic activities of Seliciclib. Investigational Semaxanib Digitoxin may decrease the cardiotoxic activities of Semaxanib. Investigational Semustine Digitoxin may decrease the cardiotoxic activities of Semustine. Experimental Seocalcitol Digitoxin may decrease the cardiotoxic activities of Seocalcitol. Experimental Sertraline The serum concentration of Digitoxin can be increased when it is combined with Sertraline. Approved Sildenafil The metabolism of Digitoxin can be decreased when combined with Sildenafil. Approved, Investigational Siltuximab The serum concentration of Digitoxin can be decreased when it is combined with Siltuximab. Approved Simeprevir The serum concentration of Digitoxin can be increased when it is combined with Simeprevir. Approved Simvastatin The serum concentration of Digitoxin can be increased when it is combined with Simvastatin. Approved Sirolimus Digitoxin may decrease the cardiotoxic activities of Sirolimus. Approved, Investigational Sisomicin The serum concentration of Digitoxin can be decreased when it is combined with Sisomicin. Investigational Sitafloxacin Digitoxin may decrease the cardiotoxic activities of Sitafloxacin. Experimental Sizofiran Digitoxin may decrease the cardiotoxic activities of Sizofiran. Investigational Soblidotin Digitoxin may decrease the cardiotoxic activities of Soblidotin. Investigational Solithromycin The serum concentration of Digitoxin can be increased when it is combined with Solithromycin. Investigational Sonidegib Digitoxin may decrease the cardiotoxic activities of Sonidegib. Approved, Investigational Sorafenib Digitoxin may decrease the cardiotoxic activities of Sorafenib. Approved, Investigational Sotalol Sotalol may increase the bradycardic activities of Digitoxin. Approved SP1049C The serum concentration of Digitoxin can be decreased when it is combined with SP1049C. Investigational Sparfloxacin Digitoxin may decrease the cardiotoxic activities of Sparfloxacin. Approved Sparfosic acid Digitoxin may decrease the cardiotoxic activities of Sparfosic acid. Experimental Sparsomycin Digitoxin may decrease the cardiotoxic activities of Sparsomycin. Experimental Spectinomycin The serum concentration of Digitoxin can be decreased when it is combined with Spectinomycin. Approved, Vet Approved Spiramycin The serum concentration of Digitoxin can be increased when it is combined with Spiramycin. Approved Spironolactone The serum concentration of Digitoxin can be increased when it is combined with Spironolactone. Approved squalamine Digitoxin may decrease the cardiotoxic activities of squalamine. Investigational SRT501 Digitoxin may decrease the cardiotoxic activities of SRT501. Investigational St. John's Wort The serum concentration of Digitoxin can be decreased when it is combined with St. John's Wort. Nutraceutical Staurosporine The serum concentration of Digitoxin can be increased when it is combined with Staurosporine. Experimental Stiripentol The serum concentration of Digitoxin can be increased when it is combined with Stiripentol. Approved Streptomycin The serum concentration of Digitoxin can be decreased when it is combined with Streptomycin. Approved, Vet Approved Streptozocin Digitoxin may decrease the cardiotoxic activities of Streptozocin. Approved Succinylcholine Succinylcholine may increase the arrhythmogenic activities of Digitoxin. Approved Sulfinpyrazone The serum concentration of Digitoxin can be increased when it is combined with Sulfinpyrazone. Approved Sulfisoxazole The metabolism of Digitoxin can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Sulforaphane Digitoxin may decrease the cardiotoxic activities of Sulforaphane. Investigational Sulindac Digitoxin may decrease the cardiotoxic activities of Sulindac. Approved Sulpiride The risk or severity of adverse effects can be increased when Sulpiride is combined with Digitoxin. Approved Sumatriptan The serum concentration of Digitoxin can be increased when it is combined with Sumatriptan. Approved, Investigational Sunitinib Digitoxin may decrease the cardiotoxic activities of Sunitinib. Approved, Investigational Suramin Digitoxin may decrease the cardiotoxic activities of Suramin. Approved Tacrine The serum concentration of Digitoxin can be increased when it is combined with Tacrine. Withdrawn Tacrolimus The serum concentration of Digitoxin can be decreased when it is combined with Tacrolimus. Approved, Investigational Talaporfin Digitoxin may decrease the cardiotoxic activities of Talaporfin. Investigational Talazoparib Digitoxin may decrease the cardiotoxic activities of Talazoparib. Investigational Talinolol Talinolol may increase the bradycardic activities of Digitoxin. Investigational Tamoxifen Digitoxin may decrease the cardiotoxic activities of Tamoxifen. Approved Taselisib Digitoxin may decrease the cardiotoxic activities of Taselisib. Investigational Taurocholic Acid The serum concentration of Digitoxin can be increased when it is combined with Taurocholic Acid. Experimental Taurolidine Digitoxin may decrease the cardiotoxic activities of Taurolidine. Investigational Tegafur Digitoxin may decrease the cardiotoxic activities of Tegafur. Approved Telaprevir The metabolism of Digitoxin can be decreased when combined with Telaprevir. Withdrawn Telithromycin The metabolism of Digitoxin can be decreased when combined with Telithromycin. Approved Telmisartan The serum concentration of Digitoxin can be increased when it is combined with Telmisartan. Approved, Investigational Temafloxacin Digitoxin may decrease the cardiotoxic activities of Temafloxacin. Withdrawn Temoporfin Digitoxin may decrease the cardiotoxic activities of Temoporfin. Approved Temozolomide Digitoxin may decrease the cardiotoxic activities of Temozolomide. Approved, Investigational Temsirolimus Digitoxin may decrease the cardiotoxic activities of Temsirolimus. Approved Teniposide Digitoxin may decrease the cardiotoxic activities of Teniposide. Approved Terazosin The serum concentration of Digitoxin can be increased when it is combined with Terazosin. Approved Terfenadine The serum concentration of Digitoxin can be increased when it is combined with Terfenadine. Withdrawn Tertatolol Tertatolol may increase the bradycardic activities of Digitoxin. Experimental Tesmilifene The serum concentration of Digitoxin can be decreased when it is combined with Tesmilifene. Investigational Testolactone Digitoxin may decrease the cardiotoxic activities of Testolactone. Approved Testosterone The serum concentration of Digitoxin can be increased when it is combined with Testosterone. Approved, Investigational Tezacitabine Digitoxin may decrease the cardiotoxic activities of Tezacitabine. Investigational Thalidomide Digitoxin may decrease the cardiotoxic activities of Thalidomide. Approved, Investigational, Withdrawn Thiotepa Digitoxin may decrease the cardiotoxic activities of Thiotepa. Approved Thymalfasin Digitoxin may decrease the cardiotoxic activities of Thymalfasin. Approved, Investigational Tiazofurine Digitoxin may decrease the cardiotoxic activities of Tiazofurine. Experimental Tibolone Digitoxin may decrease the cardiotoxic activities of Tibolone. Approved Ticagrelor The serum concentration of Digitoxin can be increased when it is combined with Ticagrelor. Approved Ticlopidine The metabolism of Digitoxin can be decreased when combined with Ticlopidine. Approved Timolol Timolol may increase the bradycardic activities of Digitoxin. Approved Tioguanine Digitoxin may decrease the cardiotoxic activities of Tioguanine. Approved Tiomolibdate ion Digitoxin may decrease the cardiotoxic activities of Tiomolibdate ion. Investigational Tipifarnib Digitoxin may decrease the cardiotoxic activities of Tipifarnib. Investigational Tirapazamine Digitoxin may decrease the cardiotoxic activities of Tirapazamine. Investigational Tivozanib Digitoxin may decrease the cardiotoxic activities of Tivozanib. Investigational Tobramycin The serum concentration of Digitoxin can be decreased when it is combined with Tobramycin. Approved, Investigational Tocilizumab The serum concentration of Digitoxin can be decreased when it is combined with Tocilizumab. Approved Tolevamer The risk or severity of adverse effects can be increased when Tolevamer is combined with Digitoxin. Approved Tolvaptan The serum concentration of Digitoxin can be increased when it is combined with Tolvaptan. Approved Topotecan Digitoxin may decrease the cardiotoxic activities of Topotecan. Approved, Investigational Torasemide The risk or severity of adverse effects can be increased when Torasemide is combined with Digitoxin. Approved Toremifene Digitoxin may decrease the cardiotoxic activities of Toremifene. Approved, Investigational Tositumomab Digitoxin may decrease the cardiotoxic activities of Tositumomab. Approved Trabectedin Digitoxin may decrease the cardiotoxic activities of Trabectedin. Approved, Investigational Trametinib Digitoxin may decrease the cardiotoxic activities of Trametinib. Approved Trastuzumab Digitoxin may decrease the cardiotoxic activities of Trastuzumab. Approved, Investigational Trastuzumab emtansine Digitoxin may decrease the cardiotoxic activities of Trastuzumab emtansine. Approved Trazodone The serum concentration of Digitoxin can be decreased when it is combined with Trazodone. Approved, Investigational Trebananib Digitoxin may decrease the cardiotoxic activities of Trebananib. Investigational Tremelimumab Digitoxin may decrease the cardiotoxic activities of Tremelimumab. Investigational Treosulfan Digitoxin may decrease the cardiotoxic activities of Treosulfan. Investigational Tretazicar Digitoxin may decrease the cardiotoxic activities of Tretazicar. Investigational Tretinoin Digitoxin may decrease the cardiotoxic activities of Tretinoin. Approved, Investigational, Nutraceutical Triamterene The therapeutic efficacy of Digitoxin can be decreased when used in combination with Triamterene. Approved Triaziquone Digitoxin may decrease the cardiotoxic activities of Triaziquone. Experimental Trichlormethiazide The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Digitoxin. Approved, Vet Approved Trifluoperazine The serum concentration of Digitoxin can be increased when it is combined with Trifluoperazine. Approved Triflupromazine The serum concentration of Digitoxin can be increased when it is combined with Triflupromazine. Approved, Vet Approved Trilostane Digitoxin may decrease the cardiotoxic activities of Trilostane. Approved, Investigational, Vet Approved, Withdrawn Trimethoprim The serum concentration of Digitoxin can be decreased when it is combined with Trimethoprim. Approved, Vet Approved Trimetrexate Digitoxin may decrease the cardiotoxic activities of Trimetrexate. Approved, Investigational Trimipramine The serum concentration of Digitoxin can be increased when it is combined with Trimipramine. Approved Triptolide Digitoxin may decrease the cardiotoxic activities of Triptolide. Investigational Triptorelin Digitoxin may decrease the cardiotoxic activities of Triptorelin. Approved, Vet Approved Trofosfamide Digitoxin may decrease the cardiotoxic activities of Trofosfamide. Investigational Troleandomycin The serum concentration of Digitoxin can be increased when it is combined with Troleandomycin. Approved Trovafloxacin Digitoxin may decrease the cardiotoxic activities of Trovafloxacin. Approved, Withdrawn Troxacitabine Digitoxin may decrease the cardiotoxic activities of Troxacitabine. Investigational Tubercidin Digitoxin may decrease the cardiotoxic activities of Tubercidin. Experimental Tubocurarine Tubocurarine may increase the arrhythmogenic activities of Digitoxin. Approved Tylosin The serum concentration of Digitoxin can be increased when it is combined with Tylosin. Vet Approved Ubenimex Digitoxin may decrease the cardiotoxic activities of Ubenimex. Experimental Uracil mustard Digitoxin may decrease the cardiotoxic activities of Uracil mustard. Approved Vadimezan Digitoxin may decrease the cardiotoxic activities of Vadimezan. Investigational Valrubicin Digitoxin may decrease the cardiotoxic activities of Valrubicin. Approved Vandetanib Digitoxin may decrease the cardiotoxic activities of Vandetanib. Approved Vapreotide Digitoxin may decrease the cardiotoxic activities of Vapreotide. Approved, Investigational Vecuronium Vecuronium may increase the arrhythmogenic activities of Digitoxin. Approved Veliparib Digitoxin may decrease the cardiotoxic activities of Veliparib. Investigational Velpatasvir The serum concentration of Digitoxin can be increased when it is combined with Velpatasvir. Approved Vemurafenib Digitoxin may decrease the cardiotoxic activities of Vemurafenib. Approved Venlafaxine The metabolism of Digitoxin can be decreased when combined with Venlafaxine. Approved Verapamil The metabolism of Digitoxin can be decreased when combined with Verapamil. Approved Verteporfin Digitoxin may decrease the cardiotoxic activities of Verteporfin. Approved, Investigational Vesnarinone Digitoxin may decrease the cardiotoxic activities of Vesnarinone. Investigational Vinblastine Digitoxin may decrease the cardiotoxic activities of Vinblastine. Approved Vincristine Digitoxin may decrease the cardiotoxic activities of Vincristine. Approved, Investigational Vindesine Digitoxin may decrease the cardiotoxic activities of Vindesine. Approved Vinflunine Digitoxin may decrease the cardiotoxic activities of Vinflunine. Approved Vinorelbine Digitoxin may decrease the cardiotoxic activities of Vinorelbine. Approved, Investigational Vintafolide Digitoxin may decrease the cardiotoxic activities of Vintafolide. Investigational Vismodegib Digitoxin may decrease the cardiotoxic activities of Vismodegib. Approved Vitamin A Digitoxin may decrease the cardiotoxic activities of Vitamin A. Approved, Nutraceutical, Vet Approved Voriconazole The metabolism of Digitoxin can be decreased when combined with Voriconazole. Approved, Investigational Vorinostat Digitoxin may decrease the cardiotoxic activities of Vorinostat. Approved, Investigational Vorozole Digitoxin may decrease the cardiotoxic activities of Vorozole. Experimental Voxilaprevir The serum concentration of Digitoxin can be increased when it is combined with Voxilaprevir. Approved Zimelidine The serum concentration of Digitoxin can be increased when it is combined with Zimelidine. Withdrawn Ziprasidone The metabolism of Digitoxin can be decreased when combined with Ziprasidone. Approved Zoptarelin doxorubicin The serum concentration of Digitoxin can be decreased when it is combined with Zoptarelin doxorubicin. Investigational Zorubicin Digitoxin may decrease the cardiotoxic activities of Zorubicin. Experimental Zuretinol acetate Digitoxin may decrease the cardiotoxic activities of Zuretinol acetate. Investigational - Food Interactions
- Avoid avocado.
- Avoid bran and high fiber foods within 2 hours of taking this medication.
- Avoid excess salt/sodium unless otherwise instructed by your physician.
- Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.
- Avoid salt substitutes containing potassium.
- Limit garlic, ginger, gingko, and horse chestnut.
References
- General References
- Belz GG, Breithaupt-Grogler K, Osowski U: Treatment of congestive heart failure--current status of use of digitoxin. Eur J Clin Invest. 2001;31 Suppl 2:10-7. [PubMed:11525233]
- Kurowski V, Iven H, Djonlagic H: Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies. Intensive Care Med. 1992;18(7):439-42. [PubMed:1469187]
- Johansson S, Lindholm P, Gullbo J, Larsson R, Bohlin L, Claeson P: Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells. Anticancer Drugs. 2001 Jun;12(5):475-83. [PubMed:11395576]
- Hippius M, Humaid B, Sicker T, Hoffmann A, Gottler M, Hasford J: Adverse drug reaction monitoring--digitoxin overdosage in the elderly. Int J Clin Pharmacol Ther. 2001 Aug;39(8):336-43. [PubMed:11515708]
- External Links
- ATC Codes
- C01AA04 — Digitoxin
- MSDS
- Download (73.4 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Cystic Fibrosis (CF) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Dosage forms
Form Route Strength Tablet Oral .1 mg - Prices
Unit description Cost Unit Digitoxin powder 486.85USD g DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 255.5 °C PhysProp water solubility 3.9 mg/L (at 25 °C) YALKOWSKY,SH & DANNENFELSER,RM (1992) logP 1.85 SANGSTER (1993) - Predicted Properties
Property Value Source Water Solubility 0.0289 mg/mL ALOGPS logP 2.33 ALOGPS logP 3.6 ChemAxon logS -4.4 ALOGPS pKa (Strongest Acidic) 7.18 ChemAxon pKa (Strongest Basic) 0.24 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 12 ChemAxon Hydrogen Donor Count 5 ChemAxon Polar Surface Area 182.83 Å2 ChemAxon Rotatable Bond Count 7 ChemAxon Refractivity 191.72 m3·mol-1 ChemAxon Polarizability 83.58 Å3 ChemAxon Number of Rings 8 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9718 Blood Brain Barrier - 0.557 Caco-2 permeable - 0.8386 P-glycoprotein substrate Substrate 0.8528 P-glycoprotein inhibitor I Inhibitor 0.5557 P-glycoprotein inhibitor II Non-inhibitor 0.6021 Renal organic cation transporter Non-inhibitor 0.8473 CYP450 2C9 substrate Non-substrate 0.8687 CYP450 2D6 substrate Non-substrate 0.9116 CYP450 3A4 substrate Substrate 0.7407 CYP450 1A2 substrate Non-inhibitor 0.8902 CYP450 2C9 inhibitor Non-inhibitor 0.9082 CYP450 2D6 inhibitor Non-inhibitor 0.9412 CYP450 2C19 inhibitor Non-inhibitor 0.9258 CYP450 3A4 inhibitor Non-inhibitor 0.901 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9381 Ames test Non AMES toxic 0.9233 Carcinogenicity Non-carcinogens 0.9637 Biodegradation Not ready biodegradable 0.9671 Rat acute toxicity 4.4764 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9812 hERG inhibition (predictor II) Inhibitor 0.7759
Spectra
- Mass Spec (NIST)
- Download (12.6 KB)
- Spectra
Spectrum Spectrum Type Splash Key Mass Spectrum (Electron Ionization) MS splash10-052g-9620000000-5ddc0df4702d2f0b8581 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available 13C NMR Spectrum 1D NMR Not Applicable
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as cardenolide glycosides and derivatives. These are compounds containing a carbohydrate glycosidically bound to the cardenolide moiety.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Steroid lactones
- Direct Parent
- Cardenolide glycosides and derivatives
- Alternative Parents
- Steroidal glycosides / Oligosaccharides / 14-hydroxysteroids / O-glycosyl compounds / Oxanes / Butenolides / Tertiary alcohols / Enoate esters / Secondary alcohols / Cyclic alcohols and derivatives show 7 more
- Substituents
- Cardanolide-glycoside / Steroidal glycoside / Oligosaccharide / 14-hydroxysteroid / Hydroxysteroid / Glycosyl compound / O-glycosyl compound / 2-furanone / Oxane / Cyclic alcohol show 19 more
- Molecular Framework
- Aliphatic heteropolycyclic compounds
- External Descriptors
- cardenolide glycoside (CHEBI:28544) / cardanolide, Cardanolides and derivatives, Cardanolide and derivatives, Cardiac glycosides (C06955) / Cardanolides and derivatives (LMST01120018)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Steroid hormone binding
- Specific Function
- This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...
- Gene Name
- ATP1A1
- Uniprot ID
- P05023
- Uniprot Name
- Sodium/potassium-transporting ATPase subunit alpha-1
- Molecular Weight
- 112895.01 Da
References
- Chen JJ, Wang PS, Chien EJ, Wang SW: Direct inhibitory effect of digitalis on progesterone release from rat granulosa cells. Br J Pharmacol. 2001 Apr;132(8):1761-8. [PubMed:11309248]
- Marcus FI, Ryan JN, Stafford MG: The reactivity of derivatives of digoxin and digitoxin as measured by the Na-K-atpase displacement assay and by radioimmunoassay. J Lab Clin Med. 1975 Apr;85(4):610-20. [PubMed:123547]
- Prignitz R, Frohlich D, Hoffmeister G: [Influence of roentgen rays on electrolyte changes and metabolism of the myocardium. VII. Radiation-induced inhibition of the sodium- and potassium--activated microscomal-trasport ATPase]. Strahlentherapie. 1976 Apr;151(4):356-65. [PubMed:131389]
- Bluschke V, Bonn R, Greeff K: Increase in the (Na+ + K+)-ATPase activity in heart muscle after chronic treatment with digitoxin or potassium deficient diet. Eur J Pharmacol. 1976 May;37(1):189-91. [PubMed:132355]
- Fricke U: [New aspects on the mode of action of cardiac glycosides]. Fortschr Med. 1976 Nov 11;94(32):1037-45. [PubMed:136410]
- Hauck C, Potter T, Bartz M, Wittwer T, Wahlers T, Mehlhorn U, Scheiner-Bobis G, McDonough AA, Bloch W, Schwinger RH, Muller-Ehmsen J: Isoform specificity of cardiac glycosides binding to human Na+,K+-ATPase alpha1beta1, alpha2beta1 and alpha3beta1. Eur J Pharmacol. 2009 Nov 10;622(1-3):7-14. doi: 10.1016/j.ejphar.2009.08.039. Epub 2009 Sep 12. [PubMed:19751721]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen
- Specific Function
- Catalyzes the side-chain cleavage reaction of cholesterol to pregnenolone.
- Gene Name
- CYP11A1
- Uniprot ID
- P05108
- Uniprot Name
- Cholesterol side-chain cleavage enzyme, mitochondrial
- Molecular Weight
- 60101.87 Da
References
- Wang SW, Lin H, Hwang JJ, Wang PS: Inhibition of testosterone secretion by digitoxin in rat testicular interstitial cells. J Cell Biochem. 1999 Jul 1;74(1):74-80. [PubMed:10381263]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Carriers
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
References
- Hage DS, Sengupta A: Characterisation of the binding of digitoxin and acetyldigitoxin to human serum albumin by high-performance affinity chromatography. J Chromatogr B Biomed Sci Appl. 1999 Mar 5;724(1):91-100. [PubMed:10202961]
- Dasgupta A, Vega AE, Wells A, Datta P: Sensitive methods for determination of free digitoxin concentration using digitoxin immunoassays: demonstration of elevated free digitoxin concentration caused by digitoxin-phenytoin interaction by applying these new techniques. Ther Drug Monit. 1999 Dec;21(6):625-30. [PubMed:10604823]
- Datta P, Dasgupta A: Interactions between drugs and Asian medicine: displacement of digitoxin from protein binding site by bufalin, the constituent of Chinese medicines Chan Su and Lu-Shen-Wan. Ther Drug Monit. 2000 Apr;22(2):155-9. [PubMed:10774625]
- Dasgupta A, Paul A, Wells A: Uremic sera contain inhibitors that block digitoxin-valproic acid interaction. Am J Med Sci. 2001 Oct;322(4):204-8. [PubMed:11678517]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
- Gene Name
- SLCO1A2
- Uniprot ID
- P46721
- Uniprot Name
- Solute carrier organic anion transporter family member 1A2
- Molecular Weight
- 74144.105 Da
References
- Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. [PubMed:8786566]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Organic anion transporter, capable of transporting pharmacological substances such as digoxin, ouabain, thyroxine, methotrexate and cAMP. May participate in the regulation of membrane transport of ...
- Gene Name
- SLCO4C1
- Uniprot ID
- Q6ZQN7
- Uniprot Name
- Solute carrier organic anion transporter family member 4C1
- Molecular Weight
- 78947.525 Da
References
- Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, Masuda S, Tokui T, Eto N, Abe M, Satoh F, Unno M, Hishinuma T, Inui K, Ito S, Goto J, Abe T: Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3569-74. Epub 2004 Mar 1. [PubMed:14993604]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- Pauli-Magnus C, Murdter T, Godel A, Mettang T, Eichelbaum M, Klotz U, Fromm MF: P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin. Naunyn Schmiedebergs Arch Pharmacol. 2001 Mar;363(3):337-43. [PubMed:11284449]
Drug created on July 08, 2007 11:03 / Updated on October 02, 2017 04:58